The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Official Title: An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Study ID: NCT01947608
Brief Summary: Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK(+) NSCLC.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
Banner MDACC, Gilbert, Arizona, United States
Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Highlands Oncology Group, Fayetteville, Arkansas, United States
City of Hope National Medical Center, Duarte, California, United States
Moores UCSD Cancer Center, La Jolla, California, United States
St Joseph Heritage Healthcare, Santa Rosa, California, United States
Stanford University, Stanford, California, United States
Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, United States
Advanced Medical Specialties, Miami, Florida, United States
Peachtree Hematology/Oncology Consultants, Atlanta, Georgia, United States
Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States
Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Indiana University Health Goshen Center for Cancer, Goshen, Indiana, United States
Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States
Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
Massachusetts General Hospital Mass General, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Jackson Oncology Associates, Jackson, Mississippi, United States
Nebraska Cancer Specialist/Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Mercy Clinic Oklahoma Communities Mercy Oncology, Oklahoma City, Oklahoma, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
University of Wisconsin, Madison, Wisconsin, United States
Novartis Investigative Site, Caba, Buenos Aires, Argentina
Novartis Investigative Site, Buenos Aires, Caba, Argentina
Novartis Investigative Site, Córdoba, Cordoba, Argentina
Novartis Investigative Site, Cali, Valle Del Cauca, Colombia
Novartis Investigative Site, Monteria, , Colombia
Novartis Investigative Site, Hong Kong, , Hong Kong
Novartis Investigative Site, Kowloon, , Hong Kong
Novartis Investigative Site, Delhi, , India
Novartis Investigative Site, Amman, , Jordan
Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of
Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Ciudad De Mexico, Distrito Federal, Mexico
Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico
Novartis Investigative Site, Mexico, Distrito Federal, Mexico
Novartis Investigative Site, Taguig City, Metro Manila, Philippines
Novartis Investigative Site, Quezon City, , Philippines
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Bangkok, , Thailand
Novartis Investigative Site, Bangkok, , Thailand